SaaS Software

CT:VQ™

Maximum CONTRAST. No INJECTIONS.

Non‑contrast ventilation and perfusion from standard chest CTs

CT:VQ™ is the world’s first non‑contrast post‑processing technology that transforms routine, chest CTs into quantitative, lobar ventilation (V) and perfusion (Q) maps—without injected contrast or radioisotopes. Delivered via software-as-a-service, results are returned directly into the radiology workflow for interpretation alongside the source CT images.


FDA 510(k) Cleared, For Investigational Use Only outside of the United States.

Eligible for reimbursement under Category III CPT codes.


Trial CT:VQ™ Today



White Paper Download

Designed for you

Key Advantages

Breakthrough Features

The Non-Contrast CT:VQ™ Value-Added Solution

CT:VQ™ brings non-contrast functional lung imaging to routine CT and integrates with existing PACS, expanding access even where nuclear imaging or contrast use isn’t available. Its patient-facing report delivers clear, rapid ventilation and perfusion insights—lung volumes, lobar distribution, and representative images.

 

4DMedical CTVQ™ - Value-Add to Routine Chest CTs
4DMedical CTVQ™ – Value-Add to Routine Chest CTs

4DMedical CT:VQ™ - Report Highlights
4DMedical CT:VQ™ – Report Highlights

CT:VQ™—Non‑contrast Functional Lung Imaging, No Injections

Add functional insights to routine chest CT using existing scanners and PACS—eliminating contrast agents and supporting broader, patient‑friendly access.

Clinical Evaluation

CT:VQ™

CT:VQ™ was evaluated using three complementary approaches: Data on file, 4DMedical

1. Quantitative correlation with SPECT V/Q (standalone device performance)

Additional Analysis: CT:VQ™ perfusion heterogeneity metrics showed a stronger association with DLCO than comparable SPECT measures in the submission dataset (r²: 0.557 vs 0.380).

 

2. Reader performance study

        • Expert radiologists and nuclear medicine physicians graded regional function on CT:VQ™ and SPECT V/Q using a standardized 5‑point scale.
        • Agreement with SPECT V/Q was rated good to excellent across all lung zones.
        • Kendall’s tau by zone (all readers): 0.702–0.765, exceeding the pre-specified 0.40 target for the submission.

 

3. Case‑based review

      • Illustrative cases demonstrated clinical interpretability across multiple conditions, highlighting areas of agreement and explaining discrepancies (e.g., SPECT ventilation limited by radiotracer deposition artifacts).

Get Started